## Does a Soybean Genetics Company Hold a Key Cancer-Killing CRISPR Patent?

A St. Louis agbio startup has launched a [CRISPR](https://synbiointel.com/glossary/crispr-cas9) platform — patented since 2018 — that destroys targeted cells by chewing up both DNA and RNA simultaneously, rather than making a conventional gene edit. Confluence Genetics launched Cas-CLEAR last month, positioning it as a potential mechanism for highly targeted cancer cell killing. Independent validation has already arrived: published studies from the University of Utah and Jennifer Doudna's lab at UC Berkeley have demonstrated the technology works in targeted cell destruction, including a mouse model proof-of-concept confirmed by the Doudna group.

The core IP originated inside [Benson Hill](https://synbiointel.com/companies/benson-hill), the crop science company that filed for Chapter 11 bankruptcy protection last year and whose intellectual property subsequently folded into Confluence Genetics. The mechanism is distinct from classical [CRISPR-Cas9](https://synbiointel.com/glossary/crispr-cas9) gene editing: rather than making a single-strand cut and disengaging to permit a repair-mediated edit, Cas-CLEAR makes a cut, undergoes a conformational change, and then indiscriminately degrades both DNA and RNA — inducing cell death. Senior director of R&D Matt Begemann confirmed to St. Louis Magazine that Confluence holds the patent on the specific sequences being used by both university groups, meaning any future therapeutic licensee would need to come through the company.

---

## How Cas-CLEAR Works — and Why It's Different from Standard CRISPR

Standard [CRISPR-Cas9](https://synbiointel.com/glossary/crispr-cas9) editing relies on the cell's own repair machinery after a double-strand break. The utility is precise genetic alteration — a knock-in, knockout, or [base edit](https://synbiointel.com/glossary/base-editing) at a defined locus. Cas-CLEAR is mechanistically different. According to Begemann, the system makes a cut and then undergoes a shape change that triggers indiscriminate degradation of both DNA and RNA within the cell. The result is cell death, not editing.

The specificity argument is guide-RNA-dependent: if you can design a guide RNA targeting a cancer-specific mutation, you theoretically direct the killing activity only to cells carrying that mutation, leaving wild-type cells unaffected. Begemann described it to St. Louis Magazine as "a very targeted chemotherapy that would only kill those cancer cells and leave the normal or natural cells unaffected."

That claim carries significant weight if it holds at scale — and significant skepticism is warranted. The Doudna lab's mouse model data represents early-stage proof-of-concept, not a validated therapeutic candidate. Two critical engineering challenges remain by the company's own admission: delivery to the correct tissue and sufficiently robust cell death induction in vivo. Neither has been solved. The gap between a mouse model demonstration and a clinical-grade therapeutic is where most CRISPR programs stall.

The mechanism bears some functional resemblance to systems like [CRISPR-Cas13](https://synbiointel.com/glossary/crispr-cas13), which targets RNA rather than DNA and has been explored for diagnostics and anti-viral applications by groups including [Mammoth Biosciences](https://synbiointel.com/companies/mammoth-biosciences). Cas-CLEAR's dual DNA/RNA degradation profile, however, appears to be a distinct biochemical behavior — and the 2018 patent priority date, if it holds up to scrutiny, would predate much of the collateral-activation work in the field.

---

## The Benson Hill Bankruptcy Backstory

Context matters here. [Benson Hill](https://synbiointel.com/companies/benson-hill) was once one of the more visible agbio platforms in the Midwest, having raised substantial capital to apply machine learning and gene editing to crop improvement. Its Chapter 11 filing and the subsequent transfer of IP to Confluence Genetics represents a pattern the industry has seen repeatedly: a high-capital agbio venture fails to reach commercial scale, its scientific assets survive under a leaner successor entity, and value that was written down by investors potentially resurfaces in a different application domain.

Confluence Genetics was built around soybean improvement — using what Begemann described as "AI breeding" to develop new soybean varieties. The Cas-CLEAR discovery was, by the company's account, accidental: researchers noticed the editing chemistry was killing the bacteria used for analysis, investigated the mechanism, and found it wasn't editing at all. That the IP happened to have been filed in 2018 and is now being independently validated by top-tier academic labs is either a fortunate coincidence or a sign that the underlying biochemistry was under-explored during the Benson Hill years.

---

## Licensing Strategy and Commercial Reality

Confluence Genetics is not positioning itself as a therapeutics developer. Begemann was explicit: the company's operational focus stays on soybeans, and any oncology or antimicrobial application of Cas-CLEAR will be pursued through licensing or partnerships. The universities currently publishing on the technology are using Confluence's patented sequences, which means a commercial therapeutic program would require a licensing agreement with the company.

That's a meaningful IP position — if it's defensible. Patent claims around CRISPR mechanisms have been among the most contested in biotechnology. The priority date of 2018 predates significant commercial activity in collateral-cleavage CRISPR systems, but the breadth and enforceability of the specific claims have not been independently assessed in available public filings.

For potential partners — oncology biotechs, [cell therapy](https://synbiointel.com/glossary/cell-therapy) developers, or agricultural biotech firms exploring pathogen defense — the calculus involves weighing an early-stage, academically validated proof-of-concept against unresolved delivery challenges and an IP landscape that will require careful due diligence. The agricultural antimicrobial angle (killing antibiotic-resistant bacteria, enabling plant resistance to pathogens) may actually be the nearer-term commercial path given the lower regulatory bar versus oncology indications.

---

## Industry Trajectory

The broader signal here is one the synthetic biology sector should track: agriculture-derived CRISPR chemistry as a source of novel therapeutic mechanisms. Agbio programs have historically screened far more CRISPR variants than pharma-focused programs because plant systems tolerate aggressive biochemical exploration. The idea that "failed" plant editing chemistry could harbor clinically relevant cytotoxic mechanisms isn't far-fetched — it's a direct consequence of screening breadth.

Whether Confluence Genetics can translate an interesting patent and mouse-model data into a licensing deal with a credible therapeutic developer remains to be demonstrated. But the academic validation from Berkeley and Utah, combined with a pre-existing granted patent, gives this more substance than the typical agbio-to-pharma pivot announcement.

---

## Key Takeaways

- **Confluence Genetics launched Cas-CLEAR last month**, a CRISPR system that kills cells via DNA/RNA degradation rather than gene editing.
- **The mechanism originated in Benson Hill plant research** and was discovered accidentally when the chemistry killed analytical bacteria.
- **Confluence holds a patent granted in 2018** on the specific sequences; any therapeutic commercialization requires a license from the company.
- **Independent validation is real but early**: UC Berkeley's Doudna lab demonstrated efficacy in a mouse model; University of Utah published separately. Both used Confluence's patented sequences.
- **Two unresolved challenges** by the company's own account: delivery to target tissue and sufficient cell death magnitude in vivo.
- **Confluence will not develop the therapeutic itself** — licensing and partnerships are the stated commercialization path.
- **The agricultural antimicrobial application** (antibiotic-resistant bacteria, plant pathogens) may reach market faster than an oncology indication.

---

## Frequently Asked Questions

**What is Cas-CLEAR and how is it different from CRISPR-Cas9?**
Cas-CLEAR is a CRISPR system developed by Confluence Genetics that does not perform gene editing. Instead of making a single cut and allowing cellular repair to introduce an edit, it makes a cut, undergoes a conformational change, and then degrades both DNA and RNA indiscriminately — leading to cell death. Standard CRISPR-Cas9 edits the genome; Cas-CLEAR destroys the cell.

**Who owns the Cas-CLEAR patent?**
Confluence Genetics holds the patent, which was granted in 2018. The IP originated at Benson Hill, whose assets transferred to Confluence Genetics after Benson Hill filed for Chapter 11 bankruptcy protection last year.

**Has Cas-CLEAR been validated in animal models?**
Yes. According to Confluence Genetics senior director Matt Begemann, Jennifer Doudna's lab at UC Berkeley demonstrated the technology works in a mouse model. The University of Utah has also published independently verifying the mechanism. Both groups used Confluence's patented sequences.

**What are the remaining technical hurdles before Cas-CLEAR could become a cancer therapy?**
By Confluence Genetics' own characterization, the two primary challenges are: (1) achieving reliable delivery to the correct tissue in vivo, and (2) generating sufficiently strong cell death. Both remain unsolved at this stage.

**Will Confluence Genetics develop a cancer drug itself?**
No. The company is focused on soybean genetics and AI-driven crop breeding. Any therapeutic application of Cas-CLEAR would be pursued through licensing agreements or partnerships with other organizations. Begemann stated explicitly that commercial therapeutic use would require a license from Confluence.

**What other applications does Cas-CLEAR have beyond oncology?**
The same mechanism could potentially be used to kill antibiotic-resistant bacteria or to enable crop plants to destroy invading pathogens such as bacteria, fungi, or nematodes — applications that may face a lower regulatory bar than cancer therapeutics.